Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics

2 型糖尿病：了解其早期驱动因素和治疗之路

• 批准号: 10682747
• 负责人: TERRY L. SHEPPARD
• 金额: $ 1.32万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-05 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10682747
• 关键词: Abate; Address; Affect; Basic Science; Beta Cell; Career Mobility; Classification; Collaborations; Communication; Complications of Diabetes Mellitus; Development; Diabetes Mellitus; Diagnosis; Disease; Early Diagnosis; Education; Educational workshop; Event; Failure; Future; Glucose; Glycosylated hemoglobin A; Growth; Homeostasis; Industrialization; Insulin Resistance; Intervention; Knowledge; Learning; Legal patent; Life; Measures; Metabolic; Metabolic Diseases; Methodology; Molecular; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Organ; Outcome; Participant; Pathogenesis; Pathway interactions; Patients; Research; Research Personnel; Retinal Diseases; Scientist; Structure of beta Cell of islet; Technology; Therapeutic; Thinking; Time; Translational Research; Treatment outcome; Vision; Work; career; clinical practice; comorbidity; design; diabetes mellitus therapy; diabetes pathogenesis; improved; insight; interest; mortality; multidisciplinary; next generation; novel; off-patent; posters; precision medicine; prevent; symposium; therapeutically effective; treatment and outcome

ABSTRACT Support is requested for a Keystone Symposia conference entitled Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics, organized by Drs. Christopher Rhodes, Lora Heisler, and Martin Myers. The conference will be held in Palm Springs, CA from May 1 - 4, 2023. Early detection and consequential intervention are key to good treatment outcomes and avoidance of complications for most diseases. Arguably, this may not be the case for Type-2 diabetes (T2D) where measures of elevated glucose and HbA1C, historically related to a predicted onset of retinopathy, occur too late in the pathogenesis of the disease. This makes the need for improved markers of T2D necessary to better diagnose and treat this prevalent disease at early stages. With the advent of precision medicine, now is the time to re-examine the pathogenesis of type 2 (pre)diabetes at the molecular level. However, questions the field remain, such as: 1. Which subsets of T2D define the rate of progression to certain diabetes complications; 2. Can early molecular drivers of the disease be better identified; 3. What factors contribute to dysfunctional inter-organ communication and altered metabolic homeostasis; 4. Does pancreatic ß-cell failure really define the disease; and 5. If detected early enough, can we envision ways to reverse, or even prevent T2D? The silver lining is that with several commonly used T2D therapies coming off patent soon, this may just be conceivable. Nonetheless, there also remains a need for more effective therapeutic approaches, not just for T2D, but also for its comorbidities. Therefore, this Keystone Symposia conference will examine the current knowledge of T2D pathogenesis and the therapeutic landscape with a vision towards earlier diagnosis, as well as, towards more effective and tailored T2D treatment regime(s) that could also prevent (or significantly delay) the pathway to complications and comorbidities.

抽象的 请求支持Keystone研讨会会议标题为2型糖尿病：早期了解其 由Drs组织的司机和通往治疗学的道路。克里斯托弗·罗德斯，洛拉·海斯勒和马丁·迈尔斯。 该会议将于2023年5月1日至4日在加利福尼亚州棕榈泉举行。 早期发现和结果干预是良好治疗结果和避免的关键 大多数疾病的并发症。可以说，2型糖尿病（T2D）可能并非如此 葡萄糖和HBA1C升高的度量也与预测的视网膜病发作有关，也发生 疾病发病机理的后期。这使得需要改进的T2D标记 更好地诊断和治疗这种普遍的疾病。随着精密医学的冒险，现在是 重新检查分子水平2型糖尿病的发病机理的时间。但是，问题 该领域仍然存在，例如：1。哪个T2D子集定义了对某些糖尿病的进展率 并发症； 2。可以更好地识别该疾病的早期分子驱动因素； 3。哪些因素导致了 器官间交流和代谢稳态改变； 4。是否胰腺β-细胞衰竭 真正定义了疾病； 5。如果足够及早检测到，我们可以设想逆转的方法，甚至可以防止 T2D？一线希望是，有几种常用的T2D疗法很快就会脱离专利，这可能只是 可以想象。但是，仍然需要采用更有效的治疗方法，而不仅仅是 对于T2D，但也用于合并症。因此，这次Keystone研讨会会议将检查当前 对T2D发病机理和治疗景观的了解，以及对早期诊断的视野 因为，采取更有效和量身定制的T2D治疗方案，这也可以防止（或明显延迟） 并发症和合并症的途径。